Published in Circ Res on February 01, 2013
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 | NCT00722384
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Rapid cellular phenotyping of human pluripotent stem cell-derived cardiomyocytes using a genetically encoded fluorescent voltage sensor. Stem Cell Reports (2014) 1.11
Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res (2014) 1.09
Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. J Biomech Eng (2014) 1.08
Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol Appl Pharmacol (2013) 1.08
CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis (2013) 1.01
Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res (2015) 0.96
Developing microRNA screening as a functional genomics tool for disease research. Front Physiol (2013) 0.92
N-glycans: phenotypic homology and structural differences between myocardial cells and induced pluripotent stem cell-derived cardiomyocytes. PLoS One (2014) 0.85
Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes. Cardiovasc Res (2015) 0.85
Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases. Mol Neurobiol (2014) 0.85
Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters. Stem Cell Reports (2015) 0.84
Real-Time Force and Frequency Analysis of Engineered Human Heart Tissue Derived from Induced Pluripotent Stem Cells Using Magnetic Sensing. Tissue Eng Part C Methods (2016) 0.81
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci (2015) 0.80
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta (2016) 0.80
Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening. Adv Drug Deliv Rev (2015) 0.79
Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013. Ann Biomed Eng (2013) 0.79
Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One (2014) 0.79
An early requirement for nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthood. Dev Biol (2014) 0.79
Efficient differentiation of human embryonic stem cells to arterial and venous endothelial cells under feeder- and serum-free conditions. Stem Cell Res Ther (2015) 0.79
Prospects for In Vitro Myofilament Maturation in Stem Cell-Derived Cardiac Myocytes. Biomark Insights (2015) 0.77
Identification and purification of human induced pluripotent stem cell-derived atrial-like cardiomyocytes based on sarcolipin expression. PLoS One (2014) 0.77
Pluripotent stem cells as a platform for cardiac arrhythmia drug screening. Curr Treat Options Cardiovasc Med (2014) 0.76
Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat Protoc (2017) 0.76
Recreating the Cardiac Microenvironment in Pluripotent Stem Cell Models of Human Physiology and Disease. Trends Cell Biol (2016) 0.75
Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies. Drug Discov Today (2017) 0.75
A Systemized Approach to Investigate Ca(2+) Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes. Front Cell Dev Biol (2016) 0.75
High content screening for modulators of cardiac differentiation in human pluripotent stem cells. Methods Mol Biol (2015) 0.75
Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports (2017) 0.75
Reprogramming the cardiac field. Circ Res (2014) 0.75
G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease Modeling. Front Cell Dev Biol (2015) 0.75
Micropost arrays for measuring stem cell-derived cardiomyocyte contractility. Methods (2015) 0.75
A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives. Green Chem (2016) 0.75
Reverse engineering human neurodegenerative disease using pluripotent stem cell technology. Brain Res (2015) 0.75
Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development. Appl In Vitro Toxicol (2016) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
The impact of microRNAs on protein output. Nature (2008) 32.39
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev (2004) 16.52
Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell (2007) 12.72
Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 12.52
Control of stress-dependent cardiac growth and gene expression by a microRNA. Science (2007) 12.08
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell (2011) 6.71
Modelling the long QT syndrome with induced pluripotent stem cells. Nature (2011) 5.68
Isolation of microRNA targets by miRNP immunopurification. RNA (2007) 5.50
microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev (2008) 5.39
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature (2009) 5.37
Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol (2007) 4.96
Functional screening identifies miRNAs inducing cardiac regeneration. Nature (2012) 4.39
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev (2009) 4.23
Systematic identification of C. elegans miRISC proteins, miRNAs, and mRNA targets by their interactions with GW182 proteins AIN-1 and AIN-2. Mol Cell (2007) 4.22
Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature (2011) 4.10
Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet (2000) 3.64
Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature (2011) 3.56
A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity. Cell Stem Cell (2009) 3.55
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Navigating chemical space for biology and medicine. Nature (2004) 3.44
Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell (2009) 3.42
A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell (2010) 3.41
Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics (2009) 3.34
Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet (2008) 3.00
Measurement of intracellular calcium. Physiol Rev (1999) 2.84
Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol (2011) 2.74
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A (2010) 2.47
Exploring biology with small organic molecules. Nature (2004) 2.33
A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell (2012) 2.29
Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med (2007) 2.21
Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J (2011) 2.18
Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol (2012) 2.13
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res (2009) 2.13
A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol (2011) 2.07
Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat Biotechnol (2012) 1.94
The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res (2008) 1.94
Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med (2012) 1.93
Automated microscopy for high-content RNAi screening. J Cell Biol (2010) 1.87
Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol (2004) 1.86
Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves. Eur Heart J (2007) 1.83
Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res (2013) 1.80
Engineering myocardial tissue. Circ Res (2005) 1.75
Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ Res (2011) 1.71
Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One (2009) 1.70
Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circ Res (2008) 1.67
RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ Res (2010) 1.66
Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol (2010) 1.63
Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. Stem Cell Res (2010) 1.58
Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation. J Cell Mol Med (2012) 1.55
Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods (2005) 1.54
Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation (2012) 1.53
Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res (2010) 1.51
In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem (2011) 1.43
Simple vertebrate models for chemical genetics and drug discovery screens: lessons from zebrafish and Xenopus. Dev Dyn (2009) 1.40
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A (2009) 1.36
Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell (2012) 1.34
Electrophysiological challenges of cell-based myocardial repair. Circulation (2009) 1.30
Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci U S A (2008) 1.28
microRNAs in heart disease: putative novel therapeutic targets? Eur Heart J (2010) 1.27
Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. Circ Res (2012) 1.24
An ovine transgenic Huntington's disease model. Hum Mol Genet (2010) 1.24
Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J (2012) 1.24
Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet (2011) 1.23
Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg (2008) 1.23
Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res (2010) 1.22
Cardiotoxicity of antitumor drugs. Chem Res Toxicol (2008) 1.21
Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One (2012) 1.19
A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci U S A (1993) 1.19
Immunogenicity of pluripotent stem cells and their derivatives. Circ Res (2013) 1.19
High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J Pharmacol Toxicol Methods (2012) 1.13
Myocardial oxygen and carbohydrate consumption in fetal lambs in utero and in adult sheep. Am J Physiol (1980) 1.09
Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol (2004) 1.07
Whole-genome microRNA screening identifies let-7 and mir-18 as regulators of germ layer formation during early embryogenesis. Genes Dev (2012) 1.06
Targeting the undruggable proteome: the small molecules of my dreams. Chem Biol (2010) 1.03
Direct cardiac reprogramming: from developmental biology to cardiac regeneration. Circ Res (2013) 1.02
Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci (2007) 1.01
Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods (2004) 1.00
High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J Biol Chem (2010) 0.98
Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci U S A (2010) 1.93
Expression of all Wnt genes and their secreted antagonists during mouse blastocyst and postimplantation development. Dev Dyn (2005) 1.60
The need for transparency and good practices in the qPCR literature. Nat Methods (2013) 1.58
Wnt3a binds to several sFRPs in the nanomolar range. Biochem Biophys Res Commun (2007) 1.52
Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol (2002) 1.17
Expression of Frizzled5, Frizzled7, and Frizzled10 during early mouse development and interactions with canonical Wnt signaling. Dev Dyn (2007) 1.12
Retinoic acid signalling is required for specification of pronephric cell fate. Dev Biol (2006) 1.02
An optimized procedure for whole-mount in situ hybridization on mouse embryos and embryoid bodies. Nat Protoc (2008) 0.98
Coordinate Nodal and BMP inhibition directs Baf60c-dependent cardiomyocyte commitment. Genes Dev (2013) 0.96
Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response. J Med Chem (2012) 0.93
Quantitative transcriptomics using designed primer-based amplification. Sci Rep (2013) 0.88
Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling. J Med Chem (2012) 0.87
A Nodal-to-TGFβ cascade exerts biphasic control over cardiopoiesis. Circ Res (2012) 0.87
Expression of regulatory genes for pancreas development during murine embryonic stem cell differentiation. Int J Dev Biol (2005) 0.84
Small molecules targeting in vivo tissue regeneration. ACS Chem Biol (2014) 0.76
High content screening for modulators of cardiac differentiation in human pluripotent stem cells. Methods Mol Biol (2015) 0.75
Pit cells exclusively kill P815 tumor cells by the perforin/granzyme pathway. Comp Hepatol (2004) 0.75
Whole-mount in situ hybridization (WISH) optimized for gene expression analysis in mouse embryos and embryoid bodies. Methods Mol Biol (2014) 0.75
Integrating omics into the cardiac differentiation of human pluripotent stem cells. Wiley Interdiscip Rev Syst Biol Med (2014) 0.75